Around ten years ago, the first evidence that targeting microtubule system could be a potential strategy in slowing down neurodegeneration was reported. Several teams have been working to better shape this idea and the scientific community has now the opportunity of fishing into a large amount of data coming from in vitro and in in vivo studies. Notably, these results have driven clinical trials addressing tauopathies. Unfortunately, moving such a neuroprotective strategy from mice to men has revealed unexpected concerns and results that do not fit with the promising background. Here we aim to focus the rationale for the design of a microtubule-based therapy in neurodegeneration, look at the results achieved and discuss the future perspectives. - See more at: http://www.eurekaselect.com/148357#sthash.xkCfK9Bf.dpuf
Microtubule-directed therapeutic strategy for neurodegenerative disorders : starting from the basis and looking on the emergences / G. Cappelletti, D. Cartelli, M. Christodoulou, D. Passarella. - In: CURRENT PHARMACEUTICAL DESIGN. - ISSN 1873-4286. - 23:5(2017), pp. 784-808. [10.2174/1381612822666161214150544]
Microtubule-directed therapeutic strategy for neurodegenerative disorders : starting from the basis and looking on the emergences
G. Cappelletti;D. Cartelli;M. Christodoulou;D. Passarella
2017
Abstract
Around ten years ago, the first evidence that targeting microtubule system could be a potential strategy in slowing down neurodegeneration was reported. Several teams have been working to better shape this idea and the scientific community has now the opportunity of fishing into a large amount of data coming from in vitro and in in vivo studies. Notably, these results have driven clinical trials addressing tauopathies. Unfortunately, moving such a neuroprotective strategy from mice to men has revealed unexpected concerns and results that do not fit with the promising background. Here we aim to focus the rationale for the design of a microtubule-based therapy in neurodegeneration, look at the results achieved and discuss the future perspectives. - See more at: http://www.eurekaselect.com/148357#sthash.xkCfK9Bf.dpufFile | Dimensione | Formato | |
---|---|---|---|
2017 CurrPharmDes MicrotubulesNeuredegRevCappelletti.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
2.38 MB
Formato
Adobe PDF
|
2.38 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.